Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma

Tang, Jie; Tang, Yanxiang; Yang, Jun; Huang, Si

doi:10.1016/j.ygyno.2012.01.033

Cited by 91 publications

(90 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Jelavić et al suggested that adjuvant chemotherapy consisting of four cycles of cisplatin and ifosfamide after concomitant CRT improved the control of distant metastases 18. Tang et al19 demonstrated that using one cycle of neoadjuvant chemotherapy with paclitaxel and cisplatin before receiving radiation and two cycles of consolidation chemotherapy with the same drugs after radiotherapy at 3-week intervals improved overall and disease-free survival. Additionally, it reduced localized disease and distant metastases.…”

Section: Discussionmentioning

confidence: 99%

Adjuvant carboplatin and paclitaxel after concurrent cisplatin and radiotherapy in patients with locally advanced cervical cancer

Yavaş

Sen

et al. 2019

Int J Gynecol Cancer

View full text Add to dashboard Cite

IntroductionStandard treatment for locally advanced cervical cancer (LACC) includes concomitant chemoradiotherapy (CRT) that typically controls localized disease. However, most patients develop distant metastasis, ultimately leading to death.ObjectiveTo determine the role of adjuvant carboplatin and paclitaxel for clinical outcomes in patients with LACC.MethodsBetween 2010 and 2017, 109 patients with LACC were retrospectively evaluated. All patients received cisplatin (40 mg/m2) with concurrent external-beam radiotherapy (up to 50.4 Gy), followed by intra-cavitary brachytherapy. Forty-six of 109 patients received a median of six cycles (range 3–6 cycles) of adjuvant chemotherapy consisting of paclitaxel (175 mg/m2) and carboplatin (CRT + chemotherapy group; area under the curve 5). The remaining 63 patients did not receive adjuvant chemotherapy (CRT group).ResultsDisease-free survival and overall survival after a median follow-up of 24.5 months (range 2.6–94.75 months) were 93.5% and 95.7% and 69.8% and 82.5 % for the CRT + chemotherapy and CRT groups, respectively (p = 0.001, p = 0.012, respectively). No acute grade 3/4 gastrointestinal or genitourinary toxicities were seen during CRT. During adjuvant chemotherapy, the most troublesome side effects were hematologic and neurologic toxicities; however, most were manageable. No chronic grade 3/4 genitourinary toxicities were seen.DiscussionAdjuvant chemotherapy in patients with LACC significantly improved both disease-free survival and overall survival without increasing unmanageable toxicity. Future larger prospective trials are warranted to verify these findings.

show abstract

Section: Discussionmentioning

confidence: 99%

Adjuvant carboplatin and paclitaxel after concurrent cisplatin and radiotherapy in patients with locally advanced cervical cancer

Yavaş

Sen

et al. 2019

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Also, median survival was not statistically different between the two histological types. Other studies evaluated the timing of chemotherapy, Tang et al [33] recently evaluated the use of both neoadjuvant and adjuvant chemotherapy with concurrent chemoradiation in adenocarcinomas. In their trial, 880 patients with adenocarcinoma of the cervix were randomized to concurrent chemoradiation or concurrent chemoradiation preceded by one cycle of neoadjuvant, two cycles of adjuvant chemotherapy with cisplatin and paclitaxel were given after the completion of the treatment.…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors affecting cervical adenocarcinoma: 10 years experience in a single institution

Khalil

Bellefqih

Afif

et al. 2015

Arch Gynecol Obstet

View full text Add to dashboard Cite

show abstract

“…For example, Park et al [24] suggested that adjuvant therapy should be tailored according to postoperative risk factors in patients with early stage adenocarcinoma. Since CCRT has many adverse effects [15] [20], personalizing adjuvant therapydepending on the presence or absence of lymph node metastasis to reduce adverse effectsmay be worth considering.…”

Section: Discussionmentioning

confidence: 99%

“…Fifteen patients received neoadjuvant chemotherapy with at least one cycle of cisplatin (10 mg/body on days 1 -10 every four weeks) and 5-fluorouracil (250 mg/body on days 1 -10 every four weeks) [14]. One patient received a cycle of paclitaxel (175 mg/m 2 on day 1every three weeks) and cisplatin (75 mg/m 2 on day 1every three weeks) [15]. The remaining patients did not receive any neoadjuvant therapy.…”

Section: Methodsmentioning

confidence: 99%

Outcomes and Prognostic Factors for Adenocarcinoma/Adenosquamous Carcinomas Treated with Radical Hysterectomy and Adjuvant Therapy

Yamaguchi¹,

Yamagishi²,

Nishikawa³

et al. 2014

OJOG

View full text Add to dashboard Cite

How to cite this paper: Yamaguchi, M., et al. (2014) Overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan-Meier method and compared using the log-rank test. The prognostic significance of various clinical features was determined by using multivariate analysis with the Cox proportional hazards regression model. Results: Univariate analysis revealed that OS was significantly shorter in patients with lymph node metastasis and lymphovascular space invasion. Similarly, PFS was significantly shorter for patients with lymph node metastasis and parametrial invasion. Furthermore, multivariate analysis showed that lymph node metastasis was the only independent predictor for PFS (hazard ratio: 6.47, 95% confidence interval: 1.33 -31.44, p = 0.021). However, the use of adjuvant chemoradiotherapy did not have any significant effect on either OS or PFS, regardless of lymph node metastasis. Conclusions: Lymph node metastasis is an independent prognostic factor for poor survival in cervical AC/ASC patients treated with radical hysterectomy and adjuvant therapy. In addition, adjuvant chemoradiotherapy does not improve their survival, regardless of lymph node metastasis, which suggests that novel or personalized adjuvant therapeutic strategies with fewer adverse effects than existing strategies are needed.* Corresponding author. M. Yamaguchi et al.910

show abstract

Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma

Cited by 91 publications

References 34 publications

Adjuvant carboplatin and paclitaxel after concurrent cisplatin and radiotherapy in patients with locally advanced cervical cancer

Adjuvant carboplatin and paclitaxel after concurrent cisplatin and radiotherapy in patients with locally advanced cervical cancer

Prognostic factors affecting cervical adenocarcinoma: 10 years experience in a single institution

Outcomes and Prognostic Factors for Adenocarcinoma/Adenosquamous Carcinomas Treated with Radical Hysterectomy and Adjuvant Therapy

Contact Info

Product

Resources

About